▎WuXi AppTec Content Team Report

On January 5, NEUREGEN (Suzhou) Biomedical Technology Co., Ltd. (hereinafter referred to as "NEUREGEN") announced that in December 2023Completed Pre-A Round Financing of Tens of Millions of Yuan. This round of financingLed by Shanghai Science & Technology Investment Co. Ltd.，Wuhan Baiying, Shanghai Sinan Park Science, and Shanghai Biomedical Public Technology Service Co., Ltd. followed up with investments., the founding shareholders of NEUREGEN (including the core team) have also strategically increased their investment. This round of financing will be used to further accelerate the company's research and development progress and team building efforts.

In situ transdifferentiation is a new generation of cell reprogramming technology iteratively developed from the Nobel Prize-winning iPSC technology, representing an important breakthrough in the field of regenerative medicine.。NEUREGENFounded in December 2021,Is aAiming to leverage its in-situ cell transdifferentiation technology to develop novel gene therapy drugsBiotech Company。The company was co-founded by a professional team in the field of in situ transdifferentiation technology globally and senior experts from the gene therapy industry. The team possesses the most advanced in situ transdifferentiation technology and transformation experience internationally and within the industry, as well as successful experience across the entire drug development cycle.

Centering on the cell in-situ transdifferentiation technology, NEUREGEN has established a key R&D platform for novel gene therapy drugs, which includes core technologies such as transdifferentiation factor screening, design of viral and non-viral vectors, and the development of in vivo and in vitro pharmacodynamic methods. Currently,NEUREGEN Focuses on Developing Treatments for Neurological Disorders, with an Emphasis on Blinding Eye DiseasesAndDifficult-to-treat nervous system tumorsOriginal gene therapy drugs, and is expanding toMajor Neurodegenerative DiseasesAccording to the press release from NEUREGEN, the company also has great potential to expand into broader fields such as regenerative therapy, cancer treatment, and the emerging anti-aging sector.

Currently, NEUREGENGlioma PipelineAndRetinal Degenerative Disease PipelineAll have been supported by reliable animal experimental data and are about to enter the investigator-initiated clinical stage. Subsequent multiple pipelines will also gradually move into the preclinical research and development stage. NEUREGEN stated in a press release that based on its unique platform technology for treating various neurological diseases, it is expected to effectively address a series of unmet clinical needs, bringing new therapeutic hope to a wide range of patients.

Co-founder, Chairman and Chief Executive Officer of NEUREGENDr. Zhuchao ZhuExpressed: "Thanks to the investors in this round for their high recognition of NEUREGEN's team and core technology platform, as well as their strong support for truly original innovative technologies! Based on the advantages of large-scale screening and optimization of highly efficient transdifferentiation factors and its proprietary recombinant viral vector platform, NEUREGEN leverages a globally novel neuro-transdifferentiation technology. With a pipeline strategy that closely aligns with unmet clinical needs and its own technical characteristics, NEUREGEN is developing universal gene therapies for neurological tumors, injuries, degenerative diseases, and anti-aging. NEUREGEN will live up to its mission, continuously expand its technological advantages, rapidly advance its R&D pipeline, and contribute to bringing innovative gene therapies to patients as soon as possible."

Vice General Manager of Shanghai Science & Technology Investment Co. LtdWu JieSaid: "In situ transdifferentiation is an important development direction for gene therapy, and has achieved phased results in some indications, showing great application prospects. We value the platform value of NEUREGEN, as well as the scientific research capabilities of its core team and their valuable experience in advancing new drug development and industrialization. In the current capital environment, investors are becoming more cautious about investing in innovative drugs. We hope to return to unmet clinical 'real needs' and make meaningful investments. NEUREGEN is a pragmatic team, and we look forward to the company's pipeline bringing new treatment hopes to patients as soon as possible."

Wuhan Baiying Bio-Industry Investment Management Co., Ltd. stated: "NEUREGEN has solid underlying technical accumulation and rich industrialization experience. The company also has significant advantages in cutting-edge technology innovation and clinical value. We are optimistic about the company's potential and value in the field of in-situ transdifferentiation. Baiying Bio has long been dedicated to investing in the biopharmaceutical health sector. This collaboration also reflects our consistent commitment to supporting early-stage and original innovation projects. Moving forward, we will continue to support the company's development, believing that its platform technology can bring better innovative therapies to patients as soon as possible."

Investment Director of Shanghai Sinan Park Science Private Fund Management Co., Ltd.Qu Ji PingRepresentative stated: "The in-situ transdifferentiation technology independently developed by NEUREGEN is a new generation of cell reprogramming technology, offering innovative solutions and approaches for numerous unmet clinical needs. NEUREGEN applies this technology in two areas—tumor treatment and neural regeneration and repair—with clear clinical demand, significant market value, and development potential. Sinan Park Capital acknowledges the efforts and expertise accumulated by Dr. Zhu Chao and his team in this field. We look forward to NEUREGEN accelerating its pipeline progress and achieving product commercialization as soon as possible to benefit patients both in China and internationally. Sinan Park Capital, a subsidiary of Shanghai Lingang Group, is a private equity fund manager specializing in early-stage science and technology enterprises. Focused on cutting-edge technology sectors, it incubates and nurtures innovative companies around promising high-growth industries to build an industrial innovation ecosystem. This investment in NEUREGEN through Sinan Park Capital’s fund represents a strategic focus on novel therapies within the CGT regenerative medicine sector."

Chairman of Shanghai Biomedical Public Technology Service Co., Ltd.Li JizongStated: "NEUREGEN has obvious advantages in the innovative gene therapy of neural in-situ transdifferentiation. The essence of the biopharmaceutical industry is to originate from clinical practice, return to clinical application, and benefit the public. Under the supervision and guidance of the Shanghai Biomedical Technology Development Center, Shanghai Science & Technology Investment Co. Ltd adheres to the concept of 'investing early, investing small, and investing in hard technology,' always focusing on cutting-edge biopharmaceutical technologies, strengthening forward-looking investment layouts, fully serving the transformation of biopharmaceutical scientific and technological innovation achievements, promoting the market entry of innovative products with genuine clinical value, and benefiting public health."

Angel Investor: Partner of Jinsha River United Runpu Medical FundDr. Wang XiaoyanSaid: "The in-situ transdifferentiation technology provides a breakthrough potential treatment for neurological diseases. Since its establishment, NEUREGEN has continued to make solid business progress, and its future is promising. We will continue to empower and support the development of NEUREGEN, and look forward to the company's platform technology reaching the clinical stage as soon as possible to benefit a large number of patients."

References: